Pfizer Inc. (NYSE: PFE) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 5, the ...

Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised ...

Aug 5 - Pfizer (NYSE:PFE) heads into its Q2 earnings release amid growing investor caution. Analysts expect revenue around ...

In an upward revision of its full-year guidance, Pfizer said it now expects adjusted earnings per share for 2025 to range between 2.90 dollars and 3.10 dollars, compared to its previous forecast of ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost ...

Global pharmaceutical company Pfizer (NYSE:PFE) announced in Q2 CY2025, with sales up 10.3% year on year to $14.65 billion.

Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 ...

Pfizer (NYSE:PFE) stock gains as the company surpasses Q2 2025 expectations with $14.7B revenue and raises its full-year ...

Pfizer said the revised profit outlook reflects strong results in the first half of the year, improved cost efficiency, a ...

In terms of fundamentals, Pfizer currently boasts a market capitalization of $132 billion. Over the last twelve months, the company generated $62 billion in revenue and sustained operational ...